|
1
|
Selman WR, Laws ER Jr, Scheithauer BW and
Carpenter SM: The occurrence of dural invasion in pituitary
adenomas. J Neurosurg. 64:402–407. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scheithauer BW, Kovacs KT, Laws ER Jr and
Randall RV: Pathology of invasive pituitary tumors with special
reference to functional classification. J Neurosurg. 65:733–744.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kreutzer J and Fahlbusch R: Diagnosis and
treatment of pituitary tumors. Curr Opin Neurol. 17:693–703. 2004.
View Article : Google Scholar
|
|
4
|
Ekeblad S, Sundin A, Janson ET, Welin S,
Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd
M, Oberg K, Eriksson B and Skogseid B: Temozolomide as monotherapy
is effective in treatment of advanced malignant neuroendocrine
tumors. Clin Cancer Res. 13:2986–2991. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McCormack AI, McDonald KL, Gill AJ, Clark
SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman
AB, Robinson BG and Clifton-Bligh RJ: Low
O6-methylguanine- DNA methyltransferase (MGMT)
expression and response to temozolomide in aggressive pituitary
tumours. Clin Endocrinol. 71:226–233. 2009.
|
|
6
|
Syro LV, Uribe H, Penagos LC, Ortiz LD,
Fadul CE, Horvath E and Kovacs K: Antitumour effects of
temozolomide in a man with a large, invasive prolactin-producing
pituitary neoplasm. Clin Endocrinol. 65:552–553. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Everhard S, Kaloshi G, Criniere E,
Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari
K, Hoang-Xuan K, Delattre JY and Thillet J: MGMT methylation: a
marker of response to temozolomide in low-grade gliomas. Ann
Neurol. 60:740–743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stupp R, Hegi ME, Gilbert MR and
Chakravarti A: Chemoradiotherapy in malignant glioma: standard of
care and future directions. J Clin Oncol. 25:4127–4136. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Nifterik KA, van den Berg J, van der
Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S,
Lafleur MV, Slotman BJ, Stalpers LJ and Sminia P: Absence of the
MGMT protein as well as methylation of the MGMT promoter predict
the sensitivity for temozolomide. Br J Cancer. 103:29–35.
2010.PubMed/NCBI
|
|
10
|
Persano L, Pistollato F, Rampazzo E, Della
PA, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R and
Basso G: BMP2 sensitizes glioblastoma stem-like cells to
temozolomide by affecting HIF-1alpha stability and MGMT expression.
Cell Death Dis. 3:e4122012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiao Z, Liu Q, Zhao B, Wu J and Lei T:
Hypoxia induces hemorrhagic transformation in pituitary adenomas
via the HIF-1α signaling pathway. Oncol Rep. 26:1457–1464.
2011.PubMed/NCBI
|
|
12
|
Losa M, Mazza E, Terreni MR, McCormack A,
Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P and Reni M:
Salvage therapy with temozolomide in patients with aggressive or
metastatic pituitary adenomas: experience in six cases. Eur J
Endocrinol. 163:843–851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X
and Shi H: Chk1 knockdown confers radiosensitization in prostate
cancer stem cells. Oncol Rep. 28:2247–2254. 2012.PubMed/NCBI
|
|
14
|
Yang J, Xiao Z, Li T, Gu X and Fan B:
Erythropoietin promotes the growth of pituitary adenomas by
enhancing angiogenesis. Int J Oncol. 40:1230–1237. 2012.PubMed/NCBI
|
|
15
|
Naumann SC, Roos WP, Jost E, Belohlavek C,
Lennerz V, Schmidt CW, Christmann M and Kaina B: Temozolomide- and
fotemustine-induced apoptosis in human malignant melanoma cells:
response related to MGMT, MMR, DSBs, and p53. Br J Cancer.
100:322–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sadones J, Michotte A, Veld P, Chaskis C,
Sciot R, Menten J, Joossens EJ, Strauven T, D’Hondt LA, Sartenaer
D, et al: MGMT promoter hypermethylation correlates with a survival
benefit from temozolomide in patients with recurrent anaplastic
astrocytoma but not glioblastoma. Eur J Cancer. 45:146–153. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Nifterik KA, van den Berg J, Stalpers
LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ and Sminia P:
Differential radiosensitizing potential of temozolomide in MGMT
promoter methylated glioblastoma multiforme cell lines. Int J
Radiat Oncol Biol Phys. 69:1246–1253. 2007.PubMed/NCBI
|
|
18
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000.
View Article : Google Scholar
|
|
19
|
Neff LM, Weil M, Cole A, Hedges TR,
Shucart W, Lawrence D, Zhu JJ, Tischler AS and Lechan RM:
Temozolomide in the treatment of an invasive prolactinoma resistant
to dopamine agonists. Pituitary. 10:81–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raverot G, Sturm N, de Fraipont F, Muller
M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C,
Assaker R, et al: Temozolomide treatment in aggressive pituitary
tumors and pituitary carcinomas: a French multicenter experience. J
Clin Endocrinol Metab. 95:4592–4599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharma S, Salehi F, Scheithauer BW,
Rotondo F, Syro LV and Kovacs K: Role of MGMT in tumor development,
progression, diagnosis, treatment and prognosis. Anticancer Res.
29:3759–3768. 2009.PubMed/NCBI
|
|
22
|
Baumann P and West SC: Role of the human
RAD51 protein in homologous recombination and double-stranded-break
repair. Trends Biochem Sci. 23:247–251. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Syro LV, Ortiz LD, Scheithauer BW, Lloyd
R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K and Horvath E:
Treatment of pituitary neoplasms with temozolomide: a review.
Cancer. 117:454–462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brandes AA, Franceschi E, Tosoni A, Blatt
V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F,
Andreoli A, et al: MGMT promoter methylation status can predict the
incidence and outcome of pseudoprogression after concomitant
radiochemotherapy in newly diagnosed glioblastoma patients. J Clin
Oncol. 26:2192–2197. 2008. View Article : Google Scholar
|
|
25
|
Takeshita A, Inoshita N, Taguchi M, Okuda
C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y and Yamada S:
High incidence of low O6-methylguanine DNA
methyltransferase expression in invasive macroadenomas of Cushing’s
disease. Eur J Endocrinol. 161:553–559. 2009.
|
|
26
|
Jackson SP and Bartek J: The DNA-damage
response in human biology and disease. Nature. 461:1071–1078. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Levy A, Hall L, Yeudall WA and Lightman
SL: p53 gene mutations in pituitary adenomas: rare events. Clin
Endocrinol. 41:809–814. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hagen T, D’Amico G, Quintero M,
Palacios-Callender M, Hollis V, Lam F and Moncada S: Inhibition of
mitochondrial respiration by the anticancer agent
2-methoxyestradiol. Biochem Biophys Res Commun. 322:923–929. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pribluda VS, Gubish ER Jr, Lavallee TM,
Treston A, Swartz GM and Green SJ: 2-Methoxyestradiol: an
endogenous antiangiogenic and antiproliferative drug candidate.
Cancer Metastasis Rev. 19:173–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Verger E, Gil M, Yaya R, Vinolas N, Villa
S, Pujol T, Quinto L and Graus F: Temozolomide and concomitant
whole brain radiotherapy in patients with brain metastases: a phase
II randomized trial. Int J Radiat Oncol Biol Phys. 61:185–191.
2005. View Article : Google Scholar : PubMed/NCBI
|
